Emixustat

Drug Profile

Emixustat

Alternative Names: ACU-02; ACU-4429; ACU-4429 HCl; Emixustat HCl; Emixustat hydrochloride

Latest Information Update: 07 Jan 2017

Price : $50

At a glance

  • Originator Acucela
  • Developer Acucela; Otsuka Pharmaceutical
  • Class Cyclohexanes; Eye disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Retinoid isomerohydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Dry age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Dry age-related macular degeneration
  • Phase II Diabetic retinopathy
  • Preclinical Stargardt disease

Most Recent Events

  • 05 Jan 2017 Preclinical trials in Stargardt disease 1 in USA (PO) before January 2017
  • 05 Jan 2017 Emixustat receives Orphan Drug status for Stargardt disease 1 in USA
  • 14 Jun 2016 Otsuka Pharmaceutical terminates its co-development and co-commercialisation agreement with Acucela for emixustat (9197872; Otsuka Pharmaceuticals pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top